Blackstone and TPG agreed to acquire Hologic for up to $18.3 billion in a deal that takes the diagnostics firm private; the transaction includes contingent value rights tied to breast‑health revenue milestones. The deal, backed by institutional financing and strategic investors, will delist Hologic from Nasdaq if approved. Separately, the FDA approved Roche’s CD20 antibody Gazyva for lupus nephritis, expanding a hematology drug into a high‑need autoimmune kidney indication and creating a new competitive axis with GSK’s rival biologic.